subcutaneous recombinant human IL-15
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for subcutaneous recombinant human IL-15, covering 2022-04-29 to 2022-04-29. Get the full timeline:
Most recent: Clinical Trial Update: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) [Phase 1]